15 June 2018
El fons d'inversió Genesis Ventures, gestionat per la consultora Genesis Biomed, ha fet la seva primera inversió de 75.000 euros en el projecte de recerca NeuroHeal de l'Institut de Neurociències (INc) de la Universitat Autònoma de Barcelona (UAB) liderat per la Dra. Caty Casas. L'acord permetrà accelerar el desenvolupament del producte i avançar en la creació d'una nova spin-off.
NeuroHeal consisteix en un nou tractament de primera línia per accelerar els processos de neuroregeneració i reduir l'atròfia muscular.
Genesis Ventures, que es va presentar al Parc Científic de Barcelona el novembre de 2017, mostra la seva aposta per ...
15 June 2018
Pasqual Maragall Foundation, Banc de Sang i Teixits, Dr Oriol Mitjà and Andreu Mas-Colell have been selected as winners of the third edition of the Trifermed Awards for social impact in healthcare. The ceremony was held on June 14th at CaixaForum Barcelona with the participation of more than 300 attendees from the local and international sector.
The prizes are chaired by the researcher and neurobiologist Dra. Mara Dierseen (winner of 2017). In addition to the Dra. Dierssen, the jury was made up of Ignasi Biosca (Reig Jofre and former president of CataloniaBio), Clara Campàs (Kern Pharma and Asabys Partners), Luis ...
12 June 2018
Catalan biomedical companies attracted €102 million in investment in 2017, with €3.4 million per operation, on average. This will allow them to push forward in the development of drugs and innovative medical technology, as reflected in the Study on investment in the Biomedical industry in Catalonia: Achievements and future challenges presented today by CataloniaBio & HealthTech and EY in Barcelona. The event drew a crowd of more than 60 entrepreneurs, investors and professionals from the sector.
Venture capital continues to be the main source of funding for companies that develop products (33%), while service firms tend to opt for ...
8 June 2018
Hospital Clinic Barcelona has launched a 3D bioprinting laboratory, through a collaboration with Avinent, to print prototypes and parts for traumatology, maxillofacial surgery, otorhinolaryngology, neurosurgery and neonatology.
The lack of harmonised regulations and effective controls means this technique can't be used in patients yet, but it is a big step forward in terms of the advantages 3D printing has to offer for surgery.
Recently, Avinent was at the BIOMEDevice congress and on abusiness mission to Boston to get a first-hand look at the most innovative technology being applied in this field and to explore commercialisation opportunities.
5 June 2018
Venture capital firm Inveready, a CataloniaBio & HealthTech member, is putting the finishing touches on a €25-million fund to invest in start-ups in the health and biotechnology arena. The fund will be launched in the coming weeks, according to information from Expansión.
With this third vehicle coming soon, to be called Biotech III, Inveready will manage more than €175 million in investment. In total, they hope to build a portfolio of 20 to 25 companies, mainly in Spain.
Photo: Sara Secall and Roger Piqué at the Inveready headquarters in Barcelona - © Expansión, Elena Ramón
1 June 2018
Banco Sabadell and Asabys Partners, founded by Josep Lluís Sanfeliu and Clara Campàs —member of the last Board of directors at CataloniaBio (2014-2018)—, have created a new venture capital fund of 60 million euros which will centre its investment activity in the health arena.
The new fund is known as Sabadell Asabys Health Innovation Fund. It will carry out initial investments in biotech, MedTech and digital health companies in Spain, as well as the UK and Israel.
The fund could obtain up to 6 million euros per company, and expects to work closely with research centres and benchmark ...
23 May 2018
Bionure, member of CataloniaBio & HealthTech that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis Optica (NMO), announces the initiation of a Phase I clinical trial of its lead compound BN201 in the United Kingdom.
BN201 is a first-in-class selective SGK2 agonist that promotes remyelination and neuroprotection, offering a game-changing solution for neurodegenerative diseases.
The company has reconstituted its Board of Directors and added prominent neuro-ophthalmologist Dr. Craig Smith as the new Chief Medical Officer (CMO). Dr Smith is a Senior Advisor/Consultant with the Bill and Melinda ...
16 May 2018
For five months, a total of eleven emerging companies will receive free training and guidance...
15 May 2018
Bicosome, a CataloniaBio & HealthTech member that has developed technology to...